Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 08 04:00PM ET
27.36
Dollar change
-0.21
Percentage change
-0.76
%
Index- P/E18.21 EPS (ttm)1.50 Insider Own14.69% Shs Outstand446.69M Perf Week-3.59%
Market Cap12.26B Forward P/E6.26 EPS next Y4.37 Insider Trans0.00% Shs Float382.30M Perf Month-2.67%
Income672.90M PEG4.34 EPS next Q0.92 Inst Own70.82% Short Float3.71% Perf Quarter6.34%
Sales2.24B P/S5.48 EPS this Y-11.78% Inst Trans0.90% Short Ratio5.79 Perf Half Y-7.94%
Book/sh14.42 P/B1.90 EPS next Y10.65% ROA3.88% Short Interest14.19M Perf Year1.33%
Cash/sh4.02 P/C6.80 EPS next 5Y4.20% ROE10.56% 52W Range25.20 - 31.66 Perf YTD-2.60%
Dividend Est.0.92 (3.36%) P/FCF4.56 EPS past 5Y2.23% ROI4.78% 52W High-13.57% Beta0.46
Dividend TTM0.83 (3.03%) Quick Ratio9.35 Sales past 5Y5.78% Gross Margin- 52W Low8.57% ATR (14)0.43
Dividend Ex-DateAug 16, 2024 Current Ratio9.35 EPS Y/Y TTM165.78% Oper. Margin42.92% RSI (14)39.42 Volatility1.26% 1.43%
Employees89 Debt/Eq1.17 Sales Y/Y TTM-5.25% Profit Margin30.07% Recom1.33 Target Price44.43
Option/ShortYes / Yes LT Debt/Eq1.17 EPS Q/Q-55.20% Payout31.57% Rel Volume0.65 Prev Close27.57
Sales Surprise-3.10% EPS Surprise-0.39% Sales Q/Q-0.17% EarningsAug 08 BMO Avg Volume2.45M Price27.36
SMA20-1.95% SMA50-1.92% SMA200-3.16% Trades Volume1,585,527 Change-0.76%
Date Action Analyst Rating Change Price Target Change
Jun-03-24Downgrade UBS Buy → Neutral $28
Jun-14-22Resumed UBS Buy $47
May-13-22Initiated Scotiabank Sector Outperform $53
Apr-27-22Initiated Goldman Buy $56
Apr-14-22Upgrade JP Morgan Neutral → Overweight $50
Apr-06-22Resumed Morgan Stanley Overweight $48
Oct-29-21Upgrade Citigroup Neutral → Buy $50
Jul-30-21Initiated Tigress Financial Buy $50
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Jul-14-20Initiated Evercore ISI In-line
Sep-03-24 05:14PM
05:06PM
Aug-28-24 04:15PM
Aug-26-24 06:16AM
Aug-23-24 05:32AM
03:58PM Loading…
Aug-17-24 03:58PM
Aug-16-24 06:09PM
Aug-09-24 01:05AM
Aug-08-24 04:16PM
07:00AM
Jul-24-24 08:30AM
Jul-19-24 08:15AM
Jul-17-24 04:15PM
Jul-15-24 12:10PM
Jul-02-24 07:44PM
06:58PM Loading…
06:58PM
Jun-26-24 06:00AM
Jun-24-24 12:56PM
Jun-05-24 06:14AM
Jun-04-24 04:15PM
Jun-03-24 05:15PM
May-28-24 07:10AM
May-27-24 06:28PM
May-25-24 11:10PM
May-22-24 04:10PM
04:00PM
May-20-24 02:41PM
May-13-24 08:15AM
May-10-24 01:07AM
May-09-24 03:35PM
12:00PM Loading…
12:00PM
11:56AM
10:46AM
08:10AM
07:00AM
06:45AM
May-08-24 08:51AM
May-06-24 09:16AM
May-02-24 04:01PM
10:01AM
Apr-30-24 08:37AM
Apr-19-24 08:15AM
Apr-17-24 08:15AM
Mar-17-24 08:50AM
Feb-28-24 04:15PM
Feb-20-24 12:45PM
Feb-17-24 12:15AM
Feb-16-24 03:30PM
09:45AM
12:04AM
Feb-15-24 11:08PM
07:58AM
07:30AM
Jan-31-24 01:04AM
Jan-30-24 04:15PM
Jan-19-24 08:15AM
Jan-08-24 07:00AM
Dec-18-23 05:30AM
Nov-27-23 04:15PM
Nov-13-23 08:10AM
08:00AM
Nov-09-23 04:33PM
12:15AM
Nov-08-23 07:00AM
Oct-19-23 07:59AM
Oct-16-23 04:15PM
Oct-11-23 04:15PM
Sep-21-23 08:25AM
Sep-05-23 04:15PM
04:01PM
08:25AM
Aug-24-23 06:30AM
Aug-08-23 07:00AM
Jul-18-23 04:15PM
Jul-17-23 04:15PM
Jun-18-23 08:58AM
Jun-07-23 08:15AM
May-22-23 07:52PM
May-13-23 08:15AM
May-11-23 10:42AM
May-09-23 07:00AM
May-03-23 04:15PM
Apr-20-23 06:15AM
Apr-17-23 08:15AM
Apr-13-23 09:01AM
Apr-05-23 06:17AM
Mar-31-23 06:36AM
Mar-27-23 07:30AM
Mar-23-23 07:00AM
03:00AM
Mar-15-23 08:00AM
Mar-08-23 05:16AM
Mar-01-23 08:15AM
Feb-15-23 07:00AM
Feb-09-23 04:15PM
Feb-03-23 09:19AM
Jan-18-23 08:25AM
Jan-12-23 05:01AM
Jan-09-23 09:25AM
09:15AM
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RIGGS RORY BDirectorJan 02 '24Sale28.52235,2006,707,081254,899Jan 04 05:16 PM
RIGGS RORY BDirectorJan 03 '24Sale27.79199,0985,532,27655,801Jan 04 05:16 PM
RIGGS RORY BDirectorJan 04 '24Sale27.5535,702983,50420,099Jan 04 05:16 PM
Avara Management Ltd10% OwnerDec 29 '23Sale28.0465,8031,845,4062,477,520Jan 03 04:31 PM
Avara Management Ltd10% OwnerDec 28 '23Sale28.20209,8635,918,9342,543,323Dec 29 04:29 PM
Avara Management Ltd10% OwnerDec 27 '23Sale28.0141,7291,168,7542,753,186Dec 29 04:29 PM
Avara Management Ltd10% OwnerDec 15 '23Sale28.0110,229286,4992,794,915Dec 19 04:30 PM
Avara Management Ltd10% OwnerDec 14 '23Sale28.91364,44110,534,2762,805,144Dec 15 04:31 PM
Avara Management Ltd10% OwnerDec 13 '23Sale28.95307,9358,916,0123,169,585Dec 15 04:31 PM